HUTCHMED (China) Ltd
No enriched coverage for $HCM in the last 7 days.
No SEC Form 4 filings for $HCM in the last 30 days.
HUTCHMED (China) Limited reported first-half 2026 results, saying oncology revenues and product sales rose, supported by China and ex-U.S. performance, new label approvals, and pipeline progress. The company said it reaffirmed its guidance, citing potential upside from milestones and continued innovation investment.
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) reported 2026 interim results for six months ended June 30, 2026. China in-market sales rose 32% to $94.4m, led by ELUNATE (+41% to $60.8m) and SULANDA (+45% to $18.4m). FRUZAQLA ex-US sales grew ~70% to $68.9m. Net income attributable was $15.9m and cash was $1.37b. The company also cited multiple clinical and regulatory updates.
HUTCHMED (China) Limited (NASDAQ:HCM) reported H1 2026 revenue of $278.3M, roughly matching $277.7M in H1 2025. Oncology/Immunology revenue rose to $162.3M, with $121.4M from marketed products. China in-market oncology sales were $279.8M (+19%), led by ELUNATE and SULANDA. FRUZAQLA global in-market sales were $185.4M. The company reiterated 2026 guidance of $330–$450M and had $1.37B cash as of June 30, 2026.
Recent HCM coverage spans earnings, regulation and financial news.
The article frames accelerating oncology sales and pipeline momentum with guidance reaffirmed, supporting a bullish fundamental read-through.
The combination of accelerating in-market sales and fresh regulatory milestones (NDA acceptances and an ELUNATE approval) should support near-term sentiment and reduce binary clinical/regulatory risk.
Interim results plus multiple regulatory milestones and maintained 2026 revenue guidance create a near-term fundamental catalyst for HCM.
FRUZAQLA’s broad international approvals and strong ex-US growth are a direct demand and commercialization catalyst for HUTCHMED’s oncology revenue trajectory.
Regulatory approval expands addressable market and de-risks commercialization for savolitinib in a defined MET-amplified gastric cancer population.
alphai scores every news story that mentions HCM with an AI model for sentiment and relevance, and aggregates insider trades from HUTCHMED (China) Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
HUTCHMED (China) Limited reported first-half 2026 results, saying oncology revenues and product sales rose, supported by China and ex-U.S. performance, new label approvals, and pipeline progress. The company said it reaffirmed its guidance, citing potential upside from milestones and continued innovation investment.
1 min readHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) reported 2026 interim results for six months ended June 30, 2026. China in-market sales rose 32% to $94.4m, led by ELUNATE (+41% to $60.8m) and SULANDA (+45% to $18.4m). FRUZAQLA ex-US sales grew ~70% to $68.9m. Net income attributable was $15.9m and cash was $1.37b. The company also cited multiple clinical and regulatory updates.
7 min readHUTCHMED (China) Limited (NASDAQ:HCM) reported H1 2026 revenue of $278.3M, roughly matching $277.7M in H1 2025. Oncology/Immunology revenue rose to $162.3M, with $121.4M from marketed products. China in-market oncology sales were $279.8M (+19%), led by ELUNATE and SULANDA. FRUZAQLA global in-market sales were $185.4M. The company reiterated 2026 guidance of $330–$450M and had $1.37B cash as of June 30, 2026.
7 min readHUTCHMED reported 2026 interim results for six months ended June 30, 2026. Total revenue was $278.3 million, roughly flat vs $277.7 million in H1 2025, and net income attributable to HUTCHMED was $15.9 million. FRUZAQLA® global in-market sales reached $185.4 million, supported by launches or approvals in 41 countries. Cash was $1.37 billion.
6 min readHUTCHMED (China) said China’s NMPA granted conditional approval for ORPATHYS (savolitinib) for MET-amplified locally advanced/metastatic gastric cancer and GEJ adenocarcinoma. The company cited Phase II results (ORR 32.3%, DCR 63.1%, DoR 9.7 months, PFS 4.0 months). HCM shares rose 11.7% to 179.25p.
4 min readBiotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min readHUTCHMED shares rose 6.5% after China’s NMPA granted conditional approval for ORPATHYS® (savolitinib) for MET-amplified advanced gastric cancer/gastroesophageal junction adenocarcinoma after ≥2 prior systemic treatments. The approval cites a Phase II study with objective response rate 32.3% (as of Oct 8, 2025 cutoff) and other efficacy metrics. ORPATHYS is co-developed with AstraZeneca and commercialized by AstraZeneca.
4 min readHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) said China’s NMPA granted conditional approval for ORPATHYS (savolitinib) in locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification after ≥2 prior systemic treatments. The Phase II study (NCT04923932) reported IRC ORR 32.3% and DCR 63.1% (cutoff Oct 8, 2025).
4 min readHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) said China’s NMPA granted conditional approval to ORPATHYS (savolitinib) for locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification after ≥2 prior systemic treatments. Phase II data (NCT04923932) showed IRC-assessed ORR 32.3% (95%CI 21.2–45.1) and DCR 63.1%. AstraZeneca commercializes in China.
4 min readHUTCHMED said Phase II data for fanregratinib in advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements showed an objective response rate of 42.5% (primary endpoint) and durable activity (median duration of response 6.9 months; disease control rate 83.9%). The company added that its NDA was accepted and granted NMPA priority review in Dec 2025. Grade 3+ drug-related events occurred in 48.3%; no treatment-related deaths were reported.
5 min read
